Brought to you by:
Analyses offer a deeper dive into BEST-CLI trial data
As the vascular community continues to digest key insights from the BEST-CLI randomized controlled trial (RCT), attendees of Plenary Session 3 at the Vascular Annual Meeting (VAM) 2023, taking place 8:00–9:30a.m. Thursday morning in Potomac A/B, will be offered a…
Base revascularization strategy on effectiveness in restoring adequate and durable limb perfusion, BEST-CLI subanalysis advises
The results of a subanalysis of the BEST-CLI trial found that patients with chronic limb-threatening ischemia (CLTI) who were deemed suitable for open lower-extremity bypass surgery “have similar periprocedural complications following either open or endovascular revascularization.” The finding led researchers…
BEST-CLI vs. BASIL-2: Different questions yield different answers
Medical editor Malachi Sheahan III, MD, takes a look at seemingly conflicting results from the landmark BEST-CLI and BASIL-2 trials, and asks what they really reveal. This past April, BASIL-2 chief investigator Andrew Bradbury, MD, presented trial results at the…
BASIL-2 and BEST-CLI: A tale of two limb trials
Optimal treatment of patients with chronic limb-threatening ischemia (CLTI) has been an ongoing debate within the vascular community, fueled by growing numbers of patients, evolving technologies, provider bias, and a lack of high-quality evidence. Few randomized controlled trials (RCTs) have…
VAM 2023 beckons
Our annual gathering is almost here. After months of planning, our premiere educational event in vascular surgery, the Vascular Annual Meeting (VAM), opens June 14. Every president before me has said nothing can top this year’s event—and yet, somehow, year…
SVS webinar discusses BEST-CLI and early impacts on practice
A recording of the inaugural “SVS Presents” virtual educational session, on the BEST-CLI (Best endovascular vs. best surgical therapy in patients with critical limb ischemia) trial and its effect on vascular surgery, is now available. More than 150 people joined…
New analysis of chronic limb-threatening ischaemia patients places BEST-CLI trial into context within real-world setting
A new analysis of chronic limb-threatening ischaemia (CLTI) treatment outcomes was presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2023 Scientific Sessions (18–20 May, Phoenix, USA), a press release reports. Following the initial…
BASIL-2 points towards endovascular-first revascularization strategy in CLTI patients
A question from Manj Gohel, MD, from Cambridge University Hospitals in Cambridge, England, on what the 2023 Charing Cross (CX) International Symposium audience should take back to their multidisciplinary team meetings from the first-time presentation of BASIL-2 led chief investigator…
VAM educational sessions set to cover gamut of clinical and vascular practice matters
With sessions covering a wide swath of topics important to vascular surgeons, including many proposed by Society for Vascular Surgery (SVS) members themselves, participants at the 2023 SVS Vascular Annual Meeting (VAM) are sure to find valuable information on both…
On 45th anniversary, CX Symposium chairman credits Chicago vascular surgical tandem for enduring success
The occasion of a seminal meeting held in Chicago by former Society for Vascular Surgery (SVS) Presidents John J. Bergan, MD, and James S.T. (Jimmy) Yao, MD, played a central role in the formation of the world-renowned Charing Cross (CX)…